Skip to main content

Advertisement

SpringerLink
Log in

Posterior Reversible Encephalopathy Syndrome: A Neurologic Phenomenon in Cancer Patients

  • Neuro-oncology (M Gilbert, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Posterior reversible encephalopathy syndrome is a well-recognized entity associated with a variety of benign and malignant conditions. This syndrome typically manifests itself with headache, visual loss, and seizures. Radiographic abnormalities consist of white matter edema involving the posterior parietal and occipital lobes, manifested as increased T2 and fluid-attenuated inversion recovery signal intensity on magnetic resonance imaging. In the last decade, there has been a reported increase in the incidence of posterior reversible encephalopathy syndrome in cancer patients. The diagnosis can be challenging in this patient population. Early recognition and initiation of appropriate therapy with removal of the causative agent is essential in order to prevent permanent neurologic sequelae.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494–500.

    Article  PubMed  CAS  Google Scholar 

  2. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2007;28(7):1320–7.

    Article  PubMed  CAS  Google Scholar 

  3. Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol. 2008;29(6):1043–9.

    Article  PubMed  CAS  Google Scholar 

  4. Lamy C, Oppenheim C, Meder JF, Mas JL. Neuroimaging in posterior reversible encephalopathy syndrome. J Neuroimaging. 2004;14(2):89–96.

    Article  PubMed  CAS  Google Scholar 

  5. Yasuhara T, Tokunaga K, Hishikawa T, et al. Posterior reversible encephalopathy syndrome. J Clin Neurosci. 2011;18:406–9.

    Article  PubMed  Google Scholar 

  6. Li Y, Gor D, Walicki D, et al. Spectrum and potential pathogenesis of reversible posterior leukoencephalopathy syndrome. J Stroke CerebrovascDis. 2012;21(8):873–82. This is a retrospective single-center case series which identifies clinical and neuroimaging features, as well as various pathophysiologic causes of PRES.

    Article  Google Scholar 

  7. Tsukamoto S, Takeuchi M, Kawajiri C, et al. Posterior reversible encephalopathy syndrome in an adult patient with acute lymphoblastic leukemia after remission induction chemotherapy. Int J Hematol. 2012;95:204–8.

    Article  PubMed  Google Scholar 

  8. Bhatt A, Farooq MU, Majid A, Kassab M. Chemotherapy-related posterior reversible leukoencephalopathy syndrome. Nat Clin Pract Neurol. 2009;5(3):163–9.

    Article  PubMed  CAS  Google Scholar 

  9. Ni J, Zhou LX, Hao HL, et al. The clinical and radiological spectrum of posterior reversible encephalopathy syndrome: a retrospective series of 24 patients. J Neuroimaging. 2011;21:219–24. This is a retrospective single-center case series which identifies clinical and neuroimaging features of PRES.

    Article  PubMed  Google Scholar 

  10. Iwama M, Takahashi H, Takagi R, Hiraoka M. Permanent bilateral cortical blindness due to reversible posterior leukoencephalopathy syndrome. J Nippon Med Sch. 2011;78:184–8.

    Article  PubMed  Google Scholar 

  11. Liman TG, Bohner G, Heuschmann PU, et al. The clinical and radiological spectrum of posterior reversible encephalopathy syndrome: the retrospective Berlin PRES study. J Neurol. 2012;259:155–64. This is a retrospective multicenter case series which identifies clinical and neuroimaging features of PRES.

    Article  PubMed  CAS  Google Scholar 

  12. Mueller-Mang C, Mang T, Pirker A, et al. Posterior reversible encephalopathy syndrome: do predisposing risk factors make a difference in MRI appearance? Neuroradiology. 2009;51:373–83.

    Article  PubMed  Google Scholar 

  13. Munoz J, Kumar V, Hamilton J, et al. Posterior reversible encephalopathy syndrome: more than meets the eye. J Clin Oncol. 2013;31(20):360–3.

    Article  Google Scholar 

  14. Hart C, Kinney MO, McCarron MO. Posterior reversible encephalopathy syndrome and oral methotrexate. Clin Neurol Neurosurg. 2012;114:725–7.

    Article  PubMed  Google Scholar 

  15. Fugate JE, Claasseen DO, Cloft HJ. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85(5):427–32.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Hugonnet E, Da Ines D, Boby H, et al. Posterior reversible encephalopathy syndrome (PRES): features on CT and MR imaging. Diagn Interv Imaging. 2013;94:45–52. This is a review article which identifies various neuroimaging features in different clinical settings.

    Article  PubMed  CAS  Google Scholar 

  17. Roth C, Ferbert A. Posterior reversible encephalopathy syndrome: long term follow-up. J Neurol Neurosurg Psychiatry. 2010;81:773–7.

    Article  PubMed  Google Scholar 

  18. Burrus TM, Mandrekar J, Wijdicks EM, et al. Renal failure and posterior reversible encephalopathy syndrome in patients with thrombotic thrombocytopenic purpura. Arch Neurol. 2010;67(7):831–4.

    Article  PubMed  Google Scholar 

  19. Patejdl R, Borchert K, Pagumbke H, et al. Posterior reversible encephalopathy syndrome (PRES): an unusual primary manifestation of a diffuse large B-cell lymphoma. Clin Neurol Neurosurg. 2011;113:819–21.

    Article  PubMed  Google Scholar 

  20. Stubgen JP. Posterior reversible encephalopathy syndrome (PRES) after granulocyte-colony stimulating factor (G-CSF) therapy. J Neurol Sci. 2012;321:35–8.

    Article  PubMed  Google Scholar 

  21. Seet RCS, Rabinstein AA. Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment. Q J Med. 2012;105:69–75.

    Article  CAS  Google Scholar 

  22. Chen YH, Huang CH. Reversible posterior leukoencephalopathy syndrome induced by vinorelbine. Clin Breast Cancer. 2012;12(3):222–5.

    Article  PubMed  Google Scholar 

  23. Aradillas E, Arora R, Gasperino J. Methotrexate-induced posterior reversible encephalopathy syndrome. J Clin Pharm Ther. 2011;36:529–36.

    Article  PubMed  CAS  Google Scholar 

  24. Stott VL, Hurrell MA, Anderson TJ. Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed. Intern Med J. 2005;35(2):83–90.

    Article  PubMed  CAS  Google Scholar 

  25. Rajasekhar A, George Jr TJ. Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature. Oncologist. 2007;12(11):1332–5.

    Article  PubMed  CAS  Google Scholar 

  26. Abali H, Eren OO, Dizdar O, et al. Posterior leukoencephalopathy after combination chemotherapy in a patient with lymphoma. Leuk Lymphoma. 2005;46(12):1825–8.

    Article  PubMed  CAS  Google Scholar 

  27. Vieillot S, Pouessel D, de Champfleur NM, Becht C, Culine S. Reversible posterior leukoencephalopathy syndrome after carboplatin therapy. Ann Oncol. 2007;18(3):608–9.

    Article  PubMed  CAS  Google Scholar 

  28. Moris G, Ribacoba R, Gonzalez C. Delayed posterior encephalopathy syndrome following chemotherapy with oxaliplatin and gemcitabine. J Neurol. 2007;254(4):534–5.

    Article  PubMed  Google Scholar 

  29. Koopman M, Muller EW, Punt CJ. Reversible posterior leukoencephalopathy syndrome caused by bevacizumab: report of a case. Dis Colon Rectum. 2008;51(9):1425–6.

    Article  PubMed  Google Scholar 

  30. Kwon EJ, Kim SW, Kim KK, Seo HS, Kim do Y. A case of gemcitabine and Cisplatin associated posterior reversible encephalopathy syndrome. Cancer Res Treat. 2009;41(1):53–5.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Pinedo DM, Shah-Khan F, Shah PC. Reversible posterior leukoencephalopathy syndrome associated with oxaliplatin. J Clin Oncol. 2007;25(33):5320–1.

    Article  PubMed  Google Scholar 

  32. Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol. 2006;24(28):e48.

    Article  PubMed  Google Scholar 

  33. Connolly RM, Doherty CP, Beddy P, O'Byrne K. Chemotherapy induced reversible posterior leukoencephalopathy syndrome. Lung Cancer. 2007;56(3):459–63.

    Article  PubMed  Google Scholar 

  34. Haefner MD, Siciliano RD, Widmer LA, Vogel Wigger BM, Frick S. Reversible posterior leukoencephalopathy syndrome after treatment of diffuse large B-cell lymphoma. Onkologie. 2007;30(3):138–40.

    Article  PubMed  Google Scholar 

  35. Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet. 2000;356(9227):411–7.

    Article  PubMed  CAS  Google Scholar 

  36. Adams Jr HP, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research interdisciplinary working groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation. 2007;115(20):e478–534.

    Article  PubMed  Google Scholar 

  37. Kwon S, Koo J, Lee S. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Pediatr Neurol. 2001;24(5):361–4.

    Article  PubMed  CAS  Google Scholar 

  38. Hammerstrom AE, Howell J, Gulbis A, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. Am J Hematol. 2013;88:301–5.

    Article  PubMed  CAS  Google Scholar 

  39. Sharief U, Perry DJ. Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin. Clin Colorectal Cancer. 2009;8(3):163–5.

    Article  PubMed  CAS  Google Scholar 

  40. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006;354(9):980–2. discussion 980-2.

    Article  PubMed  Google Scholar 

  41. Wong R, Beguelin GZ, de Lima M, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2003;122(1):128–34.

    Article  PubMed  CAS  Google Scholar 

  42. Zeigler ZR, Shadduck RK, Nemunaitis J, Andrews DF, Rosenfeld CS. Bone marrow transplant-associated thrombotic microangiopathy: a case series. Bone Marrow Transplant. 1995;15(2):247–53.

    PubMed  CAS  Google Scholar 

  43. Shah-Khan F, Pinedo D, Shah P. Reversible posterior leukoencephalopathy syndrome and anti-neoplastic agents: a review. Oncol Rev. 2007;1(3):152–61.

    Article  Google Scholar 

  44. Vaughn C, Zhang L, Schiff D. Reversible posterior leukoencephalopathy syndrome in cancer. Curr Oncol Rep. 2008;10(1):86–91.

    Article  PubMed  Google Scholar 

  45. Strandgaard S, Paulson OB. Cerebrovascular consequences of hypertension. Lancet. 1994;344(8921):519–21.

    Article  PubMed  CAS  Google Scholar 

  46. Sanders AB. Hypertensive emergencies. Am Fam Physician. 1991;44(5):1767–74.

    PubMed  CAS  Google Scholar 

  47. Marinella MA, Markert RJ. Reversible posterior leukoencephalopathy syndrome associated with anticancer drugs. Intern Med J. 2008;39:826–34.

    Article  PubMed  Google Scholar 

  48. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2008;65(2):205–10.

    Article  PubMed  Google Scholar 

  49. Nuver J, Smit AJ, van der Meer J, et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol. 2005;23(36):9130–7.

    Article  PubMed  CAS  Google Scholar 

  50. Cossaart N, SantaCruz KS, Preston D, Johnson P, Skikne BS. Fatal chemotherapy-induced encephalopathy following high-dose therapy for metastatic breast cancer: a case report and review of the literature. Bone Marrow Transplant. 2003;31(1):57–60.

    Article  PubMed  CAS  Google Scholar 

  51. Kane RC, Farrell AT, Saber H, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 2006;12(24):7271–8.

    Article  PubMed  CAS  Google Scholar 

  52. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295(21):2516–24.

    Article  PubMed  CAS  Google Scholar 

  53. Tam CS, Galanos J, Seymour JF, Pitman AG, Stark RJ, Prince HM. Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol. 2004;77(1):72–6.

    Article  PubMed  CAS  Google Scholar 

  54. Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol. 2006;63(10):1475–8.

    Article  PubMed  Google Scholar 

  55. Pruitt A, Graus F, Rosenfeld M. Neurological complications of transplantation: part I: hematopoietic cell transplantation. Neurohospitalist. 2013;3(1):24–38.

    Article  PubMed Central  PubMed  Google Scholar 

  56. Reece DE, Frei-Lahr DA, Shepherd JD, et al. Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin. Bone Marrow Transplant. 1991;8(5):393–401.

    PubMed  CAS  Google Scholar 

  57. Bartynski WS, Zeigler ZR, Shadduck RK, Lister J. Pretransplantation conditioning influence on the occurrence of cyclosporine or FK-506 neurotoxicity in allogeneic bone marrow transplantation. AJNR Am J Neuroradiol. 2004;25(2):261–9.

    PubMed  Google Scholar 

  58. Zimmer WE, Hourihane JM, Wang HZ, Schriber JR. The effect of human leukocyte antigen disparity on cyclosporine neurotoxicity after allogeneic bone marrow transplantation. AJNR Am J Neuroradiol. 1998;19(4):601–8. discussion 609-10.

    PubMed  CAS  Google Scholar 

  59. Furukawa M, Terae S, Chu BC, Kaneko K, Kamada H, Miyasaka K. MRI in seven cases of tacrolimus (FK-506) encephalopathy: utility of FLAIR and diffusion-weighted imaging. Neuroradiology. 2001;43(8):615–21.

    Article  PubMed  CAS  Google Scholar 

  60. Siddiqui TS, Haq IU, Rehman B, et al. Posterior reversible encephalopathy syndrome (PRES). J Coll Physicians Surg Pak. 2012;22(3):168–70.

    PubMed  Google Scholar 

  61. Naqi R, Azeemuddin M. Posterior reversible encephalopathy syndrome. J Pak Med Assoc. 2012;62(7):657–60.

    PubMed  Google Scholar 

  62. Bartynski WS, Boardman JF, Zeigler ZR, Shadduck RK, Lister J. Posterior reversible encephalopathy syndrome in infection, sepsis, and shock. AJNR Am J Neuroradiol. 2006;27(10):2179–90.

    PubMed  CAS  Google Scholar 

  63. Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol. 1999;246(5):339–46.

    Article  PubMed  CAS  Google Scholar 

  64. Casey SO, Sampaio RC, Michel E, Truwit CL. Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol. 2000;21(7):1199–206.

    PubMed  CAS  Google Scholar 

  65. Garg RK. Posterior leukoencephalopathy syndrome. Postgrad Med J. 2001;77(903):24–8.

    Google Scholar 

  66. Lunardi N, Saraceni E, Boccagni P. Posterior reversible encephalopathy syndrome in the intensive care unit after liver transplant: A comparison of our experience with the existing literature. Minerva Anestesiol. 2012;78(7):847–50.

    PubMed  CAS  Google Scholar 

  67. Di Nisio M, Soesan M, Otten HM. Endothelial damage of the internal carotid artery after chemoradiotherapy of the neck for a Hodgkin lymphoma. Thromb Haemost. 2007;97(2):315–6.

    PubMed  Google Scholar 

  68. Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol. 2002;23(6):1038–48.

    PubMed  Google Scholar 

  69. Sibai BM. Medical disorders in pregnancy, including hypertensive diseases. Curr Opin Obstet Gynecol. 1990;2(1):13–22.

    PubMed  CAS  Google Scholar 

  70. Ito T, Sakai T, Inagawa S, Utsu M, Bun T. MR angiography of cerebral vasospasm in preeclampsia. AJNR Am J Neuroradiol. 1995;16(6):1344–6.

    PubMed  CAS  Google Scholar 

  71. Bakshi R, Bates VE, Mechtler LL, Kinkel PR, Kinkel WR. Occipital lobe seizures as the major clinical manifestation of reversible posterior leukoencephalopathy syndrome: magnetic resonance imaging findings. Epilepsia. 1998;39(3):295–9.

    Article  PubMed  CAS  Google Scholar 

  72. Demirel I, Ozer AB, Bayar MK, et al. Anesthesia and intensive care management in a pregnant woman with PRES: a case report. Case Rep Anesthesiol. 2012. doi:10.1155/2012/745939.

    PubMed Central  PubMed  Google Scholar 

  73. Erdogan FF, Ozkan S. A rare entity in ED: Posterior reversible encephalopathy. Am J Emerg Med. 2099;2012(30):e1–3.

    Google Scholar 

  74. Andrews P, Azoulay E, Antonelli M, et al. Year in review in intensive care medicine, 2005. II. Infection and sepsis, ventilator-associated pneumonia, ethics, haematology and haemostasis, ICU organisation and scoring, brain injury. Intensive Care Med. 2006;32(3):380–90.

    Article  PubMed  Google Scholar 

  75. Andrews P, Azoulay E, Antonelli M, et al. Year in review in intensive care medicine, 2004. III. Outcome, ICU organisation, scoring, quality of life, ethics, psychological problems and communication in the ICU, immunity and hemodynamics during sepsis, pediatric and neonatal critical care, experimental studies. Intensive Care Med. 2005;31(3):356–72.

    Article  PubMed  Google Scholar 

  76. Striano P, Striano S, Totora F, et al. Clinical spectrum and critical care management of posterior reversible encephalopathy syndrome (PRES). Med Sci Monit. 2005;11(11):549–53.

    Google Scholar 

  77. Finsterer J, Schlager T, Kopsa W, Wild E. Nitroglycerin-aggravated pre-eclamptic posterior reversible encephalopathy syndrome (PRES). Neurology. 2003;61(5):715–6.

    Article  PubMed  CAS  Google Scholar 

  78. Harkany T, Dijkstra IM, Oosterink BJ, et al. Increased amyloid precursor protein expression and serotonergic sprouting following excitotoxic lesion of the rat magnocellular nucleus basalis: neuroprotection by Ca2+ antagonist nimodipine. Neuroscience. 2000;101(1):101–14.

    Article  PubMed  CAS  Google Scholar 

  79. Rosetti AO, Lowenstein DH. Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol. 2011;10:922–30.

    Article  Google Scholar 

  80. Kozak OS, Wijdicks EF, Manno EM, Miley JT, Rabinstein AA. Status epilepticus as initial manifestation of posterior reversible encephalopathy syndrome. Neurology. 2007;69(9):894–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Eileen M. Le and Monica E. Loghin declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, P.O. Box 301402, Unit #431, Houston, TX, 77232-1402, USA

    Eileen M. Le & Monica E. Loghin

Authors
  1. Eileen M. Le
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monica E. Loghin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monica E. Loghin.

Additional information

This article is part of the Topical Collection on Neuro-oncology

Rights and permissions

Reprints and permissions

About this article

Cite this article

Le, E.M., Loghin, M.E. Posterior Reversible Encephalopathy Syndrome: A Neurologic Phenomenon in Cancer Patients. Curr Oncol Rep 16, 383 (2014). https://doi.org/10.1007/s11912-014-0383-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-014-0383-3

Keywords

Search

Navigation